CD274 and familial pancreatic carcinoma: Regarding therapeutic potential, our data in two independent syngeneic mouse models of pancreatic cancer showed the ability of AZD1390 (and a structurally related compound AZD0156) to sensitize tumors to PD-L1 immune checkpoint inhibition when given in combination with radiotherapy.